SCHEMBL27053774

SCHEMBL27053774

Cc1c(Br)c(F)cc2c(Cl)nc(Cl)nc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27053765 0.83 — —
SCHEMBL38660623 0.83 GPR35 (0.33) —
SCHEMBL29617699 0.83 HSP90AA1 (0.32) —
SCHEMBL22028855 0.83 HSP90AA1 (0.32) —
SCHEMBL24616403 0.80 AR (0.33) —
SCHEMBL29343951 0.77 — —
SCHEMBL30504349 0.75 HTT (0.36) —
SCHEMBL22101462 0.75 HTT (0.36) —
SCHEMBL29343954 0.75 KDM4E (0.33) —
SCHEMBL2919013 0.74 EPRS1 (0.37) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026101924-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2026-05-15 — — WO disclosed
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2026-01-20 — — US disclosed
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS INC (US) 2025-11-13 — — US disclosed
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2025-11-11 — — US disclosed
US-20250282799-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-09-11 — — US disclosed
US-20250179093-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-06-05 — — US disclosed
WO-2025064542-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2025-03-27 — — WO disclosed
US-20240025918-A1 KRAS G12D Inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-01-25 — — US disclosed
US-20240025918-A1 KRAS G12D Inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-01-25 — — US disclosed
Send feedback